Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

AACR was full of biotechs showcasing their preclinical Ras candidates, including Clasp Therapeutics, Verastem Oncology and BlossomHill Therapeutics. (Darren Incorvaia) After dropping headline-grabbing ...

Kestrel today announced that the first patient has been dosed in its phase 1 trial of KST-6051, an oral small molecule meant to inhibit multiple different kinds of KRAS mutations. (iStock / Getty ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

The 2026 NFL Draft is over, and now it's all about analyzing each pick and how they fit. The Washington Commanders selected six players in the 2026 draft, beginning with Ohio State linebacker Sonny ...

Gennadiy Tsygan knows how expensive it is to build a home in the United States. That’s why he imported almost everything for his dream house from China. Most of his home fixtures were imported ...

Importing is attractive, and Chinese sellers know US people want it. A growing number of Americans are turning to Chinese suppliers to cut the cost of building and renovating their homes, bypassing ...

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...

(MENAFN- GlobeNewsWire - Nasdaq) Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE ...